Abstract: Many long noncoding RNAs (lncRNAs) have been reported to be abnormally expressed in hepatocellular carcinoma (HCC), and may have the potential to serve as prognostic markers. In this study, a meta-analysis was conducted to systematically evaluate the prognostic value of various lncRNAs in HCC. Eligible literatures were systematically collected from PubMed, Embase, Web of Science, and Cochrane Library (up to December 30, 2015). The main outcomes including overall survival, relapse-free survival, and disease-free survival were analyzed. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated using random-or fixed-effects models. A total of 2,991 patients with HCC in People's Republic of China from 27 studies were included in the analysis. 
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and accounts for more than 80% of primary liver cancers. 1 With advances in surgical techniques and the development of molecular target drugs, therapeutic approaches for the treatment of HCC now can be classified into three categories: potentially curative, palliative, and symptomatic. 2, 3 However, owing to the clinical characteristics of HCC, like insidious onset, high degree of malignancy, and nonspecific symptoms in early stage, the prognosis of HCC remains dismal with a 5-year overall survival (OS) rate of 0%-10% for the reason of late detection, and HCC ranks as the second leading cause of cancer-related deaths worldwide (~745,553 deaths in 2012, 9 .1% of all cancers). Thus, the outcome of HCC patients predominantly depends on early diagnosis and a timely therapeutic treatment. As a classic biomarker for HCC diagnosis, alfa-fetoprotein submit your manuscript | www.dovepress.com
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Qu et al (AFP) is the widely used molecular marker for clinical HCC diagnosis; however, it often shows a false-positive result during pregnancy, as well as active liver disease, embryonic tumors, and certain gastrointestinal tumors. [4] [5] [6] Therefore, the identification of more sensitive and specific biomarkers for early detection of HCC is desirable and urgently needed.
During the past decades of RNA biology study, long noncoding RNAs (lncRNAs) have emerged as an essential regulator in almost all aspects of biology. 7 More importantly, accumulating evidence has demonstrated that multiple lncRNAs play an important role in tumorigenesis, 8 and their abnormal expression confers tumor initiation, cancer cell growth, and metastasis during the development of HCC, [9] [10] [11] For example, the abnormal expression of lncRNA MALAT1 and lncRNA, activated by tumor growth factor-β (lncRNA-ATB), induced EMT and cell invasion and promoted the colonization of disseminated HCC cells. 7, 12, 13 lncRNA-HEIH, as identified by microarray analysis in HCC samples, plays an oncogenic role in HCC development, which promotes in vivo tumor growth by regulating cell cycle of tumor cells. 14 In patients with HCC, correlation analysis has further emphasized the potential of lncRNAs to be used as diagnostic or prognostic markers. High expressions of lncRNA-ATB and MALAT1 can be used as robust early prognostic indicators, which suggest a poor survival of HCC patients. 12, 13 The expression level of lncRNA-HEIH in hepatitis B virus (HBV)-related HCC is significantly associated with recurrence and is an independent prognostic factor for patient's survival. 14 Using lncRNA microarrays, it has also been found that the lncRNA ZEB1-AS1 is frequently upregulated in HCC samples, especially in metastatic tumor tissues. Patients with ZEB1-AS1 hypomethylation (a tumor-specific ZEB1-AS1 promoter hypomethylation) or with high ZEB1-AS1 expression have poor recurrencefree survival (RFS).
Multiple lncRNAs, including ATB, MALAT1, HOTAIR, HEIH, ZEB1-AS1, MVIH, and GAS5, 11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] have been confirmed to be promising prognostic indicators for HCC. Among these lncRNAs, MALAT1 and HOTAIR have been comprehensively investigated in different tumors and the prognostic value of these two lncRNAs has been confirmed by systematic reviews using meta-analyses. [26] [27] [28] With the aim to gain a better insight into the prognostic value of lncRNAs in patients with HCC, we conducted a systematic review of the published articles followed by a metaanalysis to evaluate the prognostic value of these aberrantly expressed lncRNAs.
Materials and methods search strategy
The present review was performed in accordance with the standard guidelines for meta-analyses and systematic reviews of tumor marker studies. 29, 30 The research databases PubMed, Embase, Cochrane Library, and Web of Science were independently used by two authors (Zhen Qu and Chun-Hui Yuan) to obtain all relevant articles about the prognostic value of lncRNA in HCC. The literature search ended in December 30, 2015 . The search strategy used both MeSH terms and free-text words to increase the sensitivity of the search. The following search terms were used: ("Long noncoding RNA", "lncRNA", "LincRNA", "Long ncRNA", "Long intergenic non-coding RNA") AND ("hepatocellular cancer", "hepatocellular tumor", "hepatocellular carcinoma", "Hepatocellular neoplasm", "Hepatocellular neoplasm", "liver cancer", "liver tumor", "liver carcinoma", "liver neoplasm", "HCC"). All included studies were retrieved in English database together with relevant references and manual searches to implement our search.
eligibility criteria
Studies were considered eligible if they met the following criteria: patients were pathologically diagnosed with HCC, regardless of tumor-node-metastasis (TNM) stage; the expression of LncRNAs was determined in tissues from patients with HCC using quantitative reverse transcriptionpolymerase chain reaction or microarray analysis, including tumor or adjacent tissues; the prognostic value of one lncRNA was investigated; the relationship between lncRNA expression and survival (OS, relapse-free survival, and disease-free survival [DFS]) was examined; and sufficient data were provided to estimate hazard ratios (HRs) for survival rates and their 95% confidence interval (95% CI). If data subsets were published in more than one article, only the most recent one was included, and if sample population consisted of less than 20 cases, the study was excluded. The studies were restricted to human experiments, and single case reports or animal studies were excluded. All eligible studies were carefully assessed by the same two authors, and discrepancies were resolved through discussion with a third reviewer (Fu-Bing Wang).
Data quality assessment and extraction
Quality assessment was performed independently by three authors (Zhen Qu, Chun-Hui Yuan, and Fu-Bing Wang). All eligible studies were scored as our previously described method 31 and summarized in Abbreviations: DFs, disease-free survival; gaPDh, glyceraldehyde 3-phosphate dehydrogenase; lncrna, long noncoding rna; Os, overall survival; re, relative expression; rFs, relapse-free survival; rOc, receiver operating characteristic; rT-Pcr, reverse transcription-polymerase chain reaction; qrT-Pcr, quantitative reverse transcription-polymerase chain reaction.
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Qu et al independently by two authors (Zhen Qu and Chun-Hui Yuan) and they reached a consensus on all items. For each eligible study, the following information was collected: the first author, journal name, year of publication, and characteristics of the study population (including the country of the population enrolled, publication year, sample size, age, sex, stage, histological differentiation, follow-up, detective methods and items, cutoff values, and treatment data) ( Table 1) . Time-toevent data, which were used to reveal survival rate (KaplanMeier curve), were extracted to calculate the corresponding HR as per previously described methods. [31] [32] [33] [34] statistical software analysis
Statistical analysis was performed with Stata statistical software package, version 13.0 (StataCorp LP, College Station, TX, USA), and P-value less than 0.05 was considered statistically significant. Statistical heterogeneity among studies was assessed using the I 2 statistic, with significant heterogeneity defined as I 2 .50%. 35 Potential causes of heterogeneity were explored by meta-regression analyses. Pooled HRs and their associated 95% CIs were estimated using a fixed-effect model (Mantel-Haenszel), while the random-effects model was performed to summarize the statistical indicators when significant heterogeneity was present. We also conducted a one-way sensitivity analysis to evaluate the stability of the results. Publication bias was evaluated using the funnel plot with Begg's test and Egger's test. 31 
Results
eligible studies and characteristics
As shown in the flow diagram (Figure 1 ), we retrieved 806 articles from four databases. After the titles and abstracts were reviewed, 734 irrelevant or duplicate articles were excluded. A total of 72 articles were further reviewed in detail. In all, 42 articles were excluded because of no survival data to estimate HR for further analysis; three articles that reported the prognostic value of multiple lncRNAs were also excluded. 19, 36, 37 As a result, 27 published articles were included in the current meta-analysis. [11] [12] [13] [14] [15] [16] [17] [18] [20] [21] [22] [23] [24] [25] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] (Figure 2A) , while a significant heterogeneity existed between studies (I 2 =75.5%, P=0.000). (Figure 2A ). Significant heterogeneity existed across studies in the subgroup of hepatic resection, and moderate heterogeneity in the subgroups of unclear treatment. Due to the limited number of included articles about liver transplantation, the heterogeneity in this subgroup could not be calculated. Thus, we speculated that the treatment of HCC alters the predictive value of lncRNA transcription level in OS.
To explore potential sources of heterogeneity for OS, we conducted meta-regression considering following covariates: age, sex, detective method, cutoff, follow-up, HBV infection, treatment, tumor size, tumor number, AFP level, cirrhosis, TNM stage, invasion, and histological differentiation to quantify the heterogeneity. As was found in univariate analysis, no significant inter-study heterogeneity was found in these covariates (P.0.05, Figure S1 ). For meta-analysis of the association between lncRNA transcription level and OS, the funnel plot was symmetrical; Begg's test (P=0.148) and Egger's test (P=0.672) ( Figure S2 ) showed no significant publication bias across studies. Sensitivity analysis showed that neither the direction nor the magnitude of the estimated pooled results for OS was obviously affected, indicating that no single study dominated our results ( Figure S3A ), which further confirmed the stability of our results.
The prognostic significance of lncRNAs in RFS and DFS was evaluated in eleven studies [11] [12] [13] [14] [15] 18, 21, 23, 45, 47, 48 with 1,193 patients and in three studies 22, 38, 39 with 322 patients, respectively (Table 1) . lncRNA transcription level was significantly associated with RFS (HR: 2.08, 95% CI: 1.65-2.61, P=0.000) with no significant heterogeneity (I 2 =24.0%, P=0.215) ( Figure 2B ). Sensitivity analysis was not changed after omitting any of the included studies in RFS ( Figure S3B ). However, it showed that high lncRNA transcription level was not associated with DFS in HCC (HR: 1.39, 95% CI: 0.51-3.78, P=0.524) with obvious heterogeneity (I 2 =81.3%, P=0.005) ( Figure 2C ). Metaregression analysis, sensitivity analysis, and assessment of publication bias were not performed due to the relatively little heterogeneity across studies or limited number of included articles.
correlation of lncrnas with clinicopathological characteristics of hcc
The association between lncRNAs and clinicopathological characteristics was analyzed with relative risk (RR); RR .1 implied that lncRNA was associated with parameter. In HCC, high lncRNA transcription level was significantly associated with tumor size (.5 cm vs #5 cm: RR =1. 19 Table 2) .
Discussion
Up to now, the treatments for HCC are still limited, and most of them are only available to the early stage. In the later stages, traditional chemotherapy has only marginal effects and may accompany with serious side effects. Thus, novel molecular markers that can help in early diagnosis and prognosis evaluation are still urgently needed. 7 In recent years, numerous studies have demonstrated that lncRNAs are involved in various biological processes, including cancer progression and metastasis. 51 More importantly, aberrant expression of multiple lncRNAs was found to be involved in the tumorigenesis and may have prognostic potential of HCC.
In this meta-analysis, we examined the prognostic role of these lncRNAs in HCC and the relation between lncRNAs and clinicopathological characteristics. Meta-regression analysis and sensitivity analysis were performed in the current study, as well as subgroup analysis in a fixed or random model, which enhanced the statistical power to confirm the prognostic potential of these lncRNAs in HCC. A total of 27 studies comprising 25 lncRNAs and 2,991 patients were included into this meta-analysis. Pooled data analyses confirmed that high lncRNA transcription level represents a significant risk factor for both OS (HR: 1.68, 95% CI: 1.20-2.34, P=0.002) and RFS (HR: 2.08, 95% CI: 1.65-2.61, P=0.000), and significantly increased risk for death and disease recurrence. As a significant heterogeneity (I 2 =75.5%, P,0.001) was observed between studies in OS analysis, we then conducted subgroup and meta-regression analyses to quantify the heterogeneity. In subgroup analysis, different
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abnormal expression of lncrnas in hepatocellular carcinoma treatments changed the overall result, while this result was not confirmed in meta-regression analysis. Considering that HCC patients enrolled in most articles were treated with hepatic resection, and only one article reported liver transplantation, we thus could not confirm the source of heterogeneity. In future, more studies that comprised different types of treatment for HCC should be included in meta-analysis to confirm whether treatment is a source of heterogeneity.
Only three studies showed the relationship between lncRNAs and DFS, although no significant association was found in DFS (HR: 1.39, 95% CI: 0.51-3.78, P=0.524); we could not draw a definite conclusion as more studies with large sample size are needed.
Moreover, we evaluated the correlation of lncRNA transcription level with the main clinicopathological parameters of HCC; subgroup analysis showed that lncRNA transcription 11 lai et al, 13 Yang et al, 14 Wang et al, 16 Peng et al, 17 Deng et al, 18 hu et al, 20 Yuan et al, 21 Wang et al, 22 li et al, 23 Xu et al, 25 Zhang et al, 38 Yang et al, 39 shi et al, 40 Tu et al, 41 Yan et al, 43 Ding et al, 45 Wang et al, 47 11 lai et al, 13 Yang et al, 14 Yuan et al, 15 Wang et al, 16 Peng et al, 17 Deng et al, 18 Wang et al, 22 li et al, 23 Xu et al, 25 Zhang et al, 38 shi et al, 40 Tu et al, 41 Yan et al, 43 Ding et al, 45 Wang et al, 47 Wang et al 48 Tumor number (multi vs single) 11 lai et al, 13 Yuan et al, 15 Peng et al, 17 hu et al, 20 Wang et al, 22 li et al, 23 Xu et al, 25 Zhang et al, 38 Yang et al, 39 Tu et al, 41 Yan et al, 43 53 and histological differentiation 54 were associated with an unfavorable outcome in HCC patients; however, no significant association was found between lncRNA transcription level and HBV infection (positive vs negative: RR =0.83, 95% CI: 0.67-1.03), cirrhosis (Yes vs No: RR =0.94, 95% CI: 0.67-1.32), and TNM stage (III/IV vs I/II: RR =1.11, 95% CI: 0.79-1.56), as well as AFP level, tumor number, and histological differentiation. One potential explanation for these differences might be that the number of included studies was relatively limited and just one study for each lncRNA in most cases; thus, the relationship between lncRNAs and clinicopathological features was underestimated.
Furthermore, only lncRNA GAS5 and PVT1 were reported twice in this meta-analysis, and the pooled HR of these two lncRNAs were 0. 43 (Figure S4 ), which showed no prognostic value in HCC development. GAS5 exhibited tumor-suppressive activities in HCCs through negative regulation of miR-21 and proteins involved in regulating migration and invasion of cancer cells, like PTEN and vimentin. 55 Furthermore, it also was an independent prognostic factor for patients with HCC. The diminished prognostic value in our study may be owing to the complicated network among lncRNA, miRNA, and proteins.
It should be emphasized that there are several limitations in our study. Firstly, because all the patients enrolled in the articles of this meta-analysis were Chinese, the results of this study cannot be extended to all populations; secondly, different lncRNAs were used to assess the prognosis of HCC, and there was a lack of specific HCC-related lncRNA for clinical evaluation; thirdly, since there was only one study for each lncRNA in most cases, the prognostic value of each lncRNA may be overestimated. What is more, unlike serum, detection of lncRNAs within tumor tissues makes it more difficult in clinical application. Finally, substantial heterogeneity was shown across the included studies.
In conclusion, the present results confirmed the strong prognostic value of lncRNA transcription level in HCC. However, in view of the limitation of studies about individual lncRNAs, in future, the prognostic value of different lncRNAs that detected in different populations are required to enroll for meta-analysis and thus confirm the clinical utility of lncRNAs in HCC prognosis evaluation.
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